247 related articles for article (PubMed ID: 10916926)
1. Companies reduce prices for HIV drugs in developing countries.
Gottlieb S
Bull World Health Organ; 2000; 78(6):862. PubMed ID: 10916926
[TBL] [Abstract][Full Text] [Related]
2. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
3. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain.
James JS
AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151
[TBL] [Abstract][Full Text] [Related]
4. Drug makers to cut prices for developing countries.
AIDS Alert; 1998 Aug; 13(8 Suppl):1-2. PubMed ID: 11365655
[TBL] [Abstract][Full Text] [Related]
5. GATT and the gap: how to save lives.
James JS
AIDS Treat News; 1998 Nov; (No 307):1, 3-6. PubMed ID: 11366123
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
Halliburton M
Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
[TBL] [Abstract][Full Text] [Related]
7. Cautious welcome for antiretroviral cost reduction in South Africa.
Baleta A
Lancet; 2000 May; 355(9217):1799. PubMed ID: 10832840
[TBL] [Abstract][Full Text] [Related]
8. Global patent police block cost-reduction efforts.
Kasper T
GMHC Treat Issues; 1999 Mar; 13(3):1-2. PubMed ID: 11366201
[TBL] [Abstract][Full Text] [Related]
9. Drug companies, UNAIDS make drugs available.
AIDS Alert; 1998 Jan; 13(1):3. PubMed ID: 11364863
[TBL] [Abstract][Full Text] [Related]
10. World Trade Organization still threatens supply of affordable AIDS drugs.
Hagmann M
Bull World Health Organ; 2002; 80(9):762-3. PubMed ID: 12378300
[No Abstract] [Full Text] [Related]
11. The (political) economics of antiretroviral treatment in developing countries.
Nattrass NJ
Trends Microbiol; 2008 Dec; 16(12):574-9. PubMed ID: 18964022
[TBL] [Abstract][Full Text] [Related]
12. Reprivatizing pharmaceutical supplies in Africa.
Turshen M
J Public Health Policy; 2001; 22(2):198-225. PubMed ID: 11469153
[TBL] [Abstract][Full Text] [Related]
13. Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries.
Orsi F; d'almeida C
Curr Opin HIV AIDS; 2010 May; 5(3):237-41. PubMed ID: 20539080
[TBL] [Abstract][Full Text] [Related]
14. A one-time-only combination: Emergency medicine exports and the TRIPS agreement under Canada's access to medicines regime.
Weber A; Mills L
Health Hum Rights; 2010 Jun; 12(1):109-22. PubMed ID: 20930258
[TBL] [Abstract][Full Text] [Related]
15. Drug companies cut HIV drug prices in the developing world.
Yamey G
BMJ; 2000 May; 320(7246):1357. PubMed ID: 10818010
[TBL] [Abstract][Full Text] [Related]
16. Glaxo drops drug prices, AIDS foundation drops suit.
AIDS Policy Law; 2003 May; 18(10):6. PubMed ID: 12809097
[No Abstract] [Full Text] [Related]
17. U.N. drug initiative hits the ground.
Cadman J
GMHC Treat Issues; 1998 Jun; 12(6):5-6. PubMed ID: 11365723
[TBL] [Abstract][Full Text] [Related]
18. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
19. Examining the production costs of antiretroviral drugs.
Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
[TBL] [Abstract][Full Text] [Related]
20. New frontier of AIDS activism: international trade rules and global access to medicines. Interview by John S. James.
Sawyer E
AIDS Treat News; 1999 Apr; (No 317):1, 5-8. PubMed ID: 11366992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
